RLAY Stock Lights Up On Vascular Anomalies Treatment Data Boost – 60% Of Patients Show Sharp Reduction In Lesion Volume

• The data highlighted the drug’s potential to deliver strong efficacy while maintaining a manageable safety profile suitable for long-term use.
• The study enrolled 32 patients with no adverse events reported.
• Relay Therapeutics is also advancing late-stage studies of Zovegalisib in breast cancer.

Shares of Relay Therapeutics, Inc. (RLAY) jumped 10% in pre-market trading on Tuesday, after the firm unveiled encouraging early-stage clinical data for its experimental treatment for patients with a rare form of vascular anomalies.

RLAY shares are on track to snap a three-session losing streak.

Meanwhile, retail sentiment flipped to ‘bullish’ from ‘bearish’ a day earlier, while message volumes were ‘high.’ RLAY was also among the top trending tickers on the platform.

RLAY’s Therapy Shows Strong Efficacy

The trial evaluating Zovegalisib in vascular anomalies demonstrated the potential benefits of selectively targeting PI3Kα mutations. PI3Kα is an enzyme that is responsible for cell growth. The data highlighted the drug’s potential to deliver strong efficacy while maintaining a manageable safety profile suitable for long-term use.

Results from the ongoing Phase 2 ReInspire study showed that 60% of evaluable patients achieved a meaningful reduction in lesion volume within 12 weeks, with nearly all patients reporting symptom improvement. Notably, even the lowest tested dose demonstrated promising activity.

The study enrolled 32 adult and adolescent patients, many of whom had previously received existing therapies such as Alpelisib or Sirolimus. Every patient remained on treatment as of the latest data cut-off, and no treatment discontinuations due to adverse events were reported.

RLAY’s Breast Cancer Treatment Pipeline

Relay Therapeutics is also advancing late-stage studies of Zovegalisib in breast cancer, broadening the drug’s development pipeline.

Earlier this year, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Zovegalisib in combination with Fulvestrant for patients with PIK3CA-mutant advanced breast cancer.

The company also shared clinical data on the Zovegalisib-Atirmociclib triplet therapy, outlined plans for a frontline breast cancer study, and announced a clinical supply agreement with Pfizer.

The stock has seen strong buying interest this year, gaining more than 43%.

Read also: DRTS Stock Gets A Pre-Market Boost – Retail Shrug Off Wider Q1 Loss Ahead Of Key Pancreatic Cancer Data Reveal This Week

For updates and corrections, email newsroom[at]stocktwits[dot]com.